A phase II single-arm study of CRS-207 with pembrolizumab (pembro) in previously treated malignant pleural mesothelioma (MPM).

被引：12

作者：

Alley, Evan W.

Tanvetyanon, Tawee

Jahan, Thierry Marie

Gandhi, Leena

Peikert, Tobias

Stevenson, James

Schlienger, Katia

Liu, Weiqun

Nair, Nitya

Honarmand, Somayeh

Kindler, Hedy L.

机构：

[1] Univ Penn, Philadelphia, PA 19104 USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[3] Univ Calif San Francisco, San Francisco, CA 94143 USA

[4] NYU, Langone Med Ctr, New York, NY USA

[5] Mayo Clin, Rochester, MN USA

[6] Cleveland Clin, Cleveland, OH 44106 USA

[7] Merck & Co Inc, Rahway, NJ 07065 USA

[8] Aduro Biotech Inc, Berkeley, CA USA

[9] Univ Chicago, Chicago, IL 60637 USA

来源：

关键词：

D O I：

10.1200/JCO.2019.37.8_suppl.29

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2